NewKerala.com

Key Points

US scientists are making breakthrough progress on single-dose vaccines for major diseases. The MIT and Scripps team developed a dual-adjuvant system that stays active in lymph nodes for weeks. Meanwhile, Russia's Sputnik V creators are applying mRNA technology to HIV prevention. Both approaches aim to create lifetime protection with just one vaccination.

Key Points: MIT Scientists Develop Single-Dose HIV and Covid Vaccines

  • Dual-adjuvant vaccine accumulates in lymph nodes for month-long immune response
  • Technology generates broader antibody diversity against HIV proteins
  • Russian Gamaleya Center developing mRNA HIV vaccine using Sputnik V platform
  • Single-dose approach mimics natural infection for stronger lifetime protection
2 min read

US scientists developing single-dose vaccines for HIV, Covid

MIT and Scripps researchers create dual-adjuvant vaccine technology that could provide lifetime protection against HIV, Covid with just one shot.

"It offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases - J. Christopher Love"

New Delhi, Aug 28

A team of scientists in the US is working to develop vaccines that can protect against HIV, Covid, and potentially other diseases, with a single dose.

The team from MIT and the Scripps Research Institute treated mice with a vaccine that combines two different adjuvants, materials that help stimulate the immune system. They found that the combination helped generate more robust immune responses.

The dual-adjuvant vaccine was found to accumulate in the lymph nodes, where white blood cells known as B cells encounter antigens and undergo rapid mutations that generate new antibodies.

The vaccine’s antigens remained there for up to a month -- allowing the immune system to build up a much greater number and diversity of antibodies against the HIV protein than the vaccine given alone or with one adjuvant.

According to MIT professor J. Christopher Love, the approach may mimic what occurs during a natural infection and could lead to an immune response so strong and broad that vaccines only need to be given once.

“It offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks,” Love said.

Separately, Russia’s Covid-19 vaccine maker is also set to develop an mRNA-based HIV vaccine, RIA Novosti, the Russian Information Agency, said.

The vaccine to be developed by Gamaleya Center in Moscow, which will trigger an immune response against the AIDS causing virus, could be ready in around two years.

The much-anticipated HIV vaccine is based on mRNA technology, the head of the institute’s epidemiology department, Vladimir Gushchin, told RIA Novosti on Wednesday.

“We are currently at the stage of creating the first antigens that will generate a broadly neutralising immune response. The success of the vaccine will depend on whether the immunogen we use can trigger a response capable of protecting against all variants,” said Vladimir Gushchin, epidemiologist at the Centre.

The Gamaleya Center also developed Sputnik V, one of the world’s first Covid-19 vaccines, which was rolled out in August 2020. The shot, showing up to 97.8 per cent efficacy with no serious side effects, has been approved in nearly 70 countries.

- IANS

Share this article:

Reader Comments

P
Priya S
After seeing how quickly COVID vaccines were developed, I'm optimistic about HIV vaccine progress. But let's ensure proper testing before rollout. Safety first! 💉
M
Michael C
Interesting that both US and Russian teams are working on similar technology. Healthy competition in science benefits everyone. Hope they share findings through WHO.
A
Ananya R
As someone working in healthcare, single-dose vaccines would revolutionize our immunization programs. The logistics would become so much simpler, especially in tribal areas.
V
Vikram M
Hope Indian pharmaceutical companies like Serum Institute are watching this closely. We need to be at the forefront of vaccine technology, not just manufacturing.
S
Sarah B
The lymph node targeting approach sounds brilliant. Mimicking natural infection response could be the breakthrough we've been waiting for. Fingers crossed for human trials! 🤞
N
Nikhil C
While this is promising, I hope the pricing will be reasonable for developing countries. Vaccine equity matters as much as the science behind it.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50